VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | PROOF: infigratinib as first-line therapy in patients with advanced CCA

VJOncology is committed to improving our service to you

Ghassan Abou-Alfa

Ghassan Abou-Alfa, MD, of Memorial Sloan-Kettering Cancer Center, New York City, NY, evaluates rationale and study design of the Phase III PROOF study (NCT03773302), investigating infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma (CCA) with FGFR2 gene fusions/translocations This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter